Navigation Links
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus

d, double-blind, placebo-controlled Phase 2 trial, 96% (351/364) elected to enter the 24-week open-label extension phase of the trial, and 92% (321/351) of those who entered completed it. Of those completing the extension phase, 78% (250/321) continue to receive LymphoStat-B in a long-term continuation study. The trial began in October 2003.

"We are encouraged that nearly all of the patients who completed the 52- week Phase 2 study chose to continue treatment in the 24-week extension phase," said William W. Freimuth, M.D., Ph.D., Vice President, Clinical Research -- Immunology, Rheumatology and Infectious Diseases, Human Genome Sciences. "Many of these patients began treatment more than three years ago and continue on treatment today. This provides us with a substantial body of data on the long-term effects of LymphoStat-B."

About the Phase 2 Trial Results

The primary objectives of the Phase 2 study were to evaluate the safety, tolerability and efficacy of LymphoStat-B plus standard of care, versus placebo plus standard of care. A total of 449 patients with active SLE were randomized to receive one of three different doses of LymphoStat-B or placebo (1, 4 or 10 mg/kg) administered intravenously over a 52-week treatment period, in addition to standard-of-care therapy. In the extension phase, all placebo patients received LymphoStat-B at a dose of 10 mg/kg, while patients in the LymphoStat-B 10 mg/kg treatment arm continued on the 10 mg/kg dose, and patients in the 1 mg/kg and 4 mg/kg LymphoStat-B treatment arms were offered the choice of continuing on the same dose or receiving LymphoStat-B at a dose of 10 mg/kg.

In June 2006, HGS reported the 52-week data from the Phase 2 trial of LymphoStat-B in patients with SLE. The 52-week results demonstrated that LymphoStat-B significantly reduced disease activity versus placebo in patients with serologically active SLE, exhibited clinically relevant biological activity, and appeared safe and well t
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
Post Your Comments:
(Date:12/14/2009)... Fla., Dec. 14 Perry Baromedical, international ... announces the launch of the Sigma Elite, with ... of the Sigma Elite is available on each ... and has a Patent Pending. ,, The Sigma ... Data Capture Via Computerized System for Each Dive ...
(Date:12/14/2009)... DENVER, Dec. 14 Corgenix Medical ... developer and marketer of diagnostic test kits, ... Massachusetts-based life sciences company, announced today a ... Galectin-3 diagnostic products in enzyme-linked immunosorbent assay ... BG Medicine is seeking regulatory clearance in ...
(Date:12/14/2009)... Inc. is pleased to announce that the United ... number 7,599,057 titled "Method and Apparatus for Detection ... company. The patent covers the core technology which ... of this patent supports the underlying strategy as ... commercialization," said Dave Dingott, CEO and President of ...
Breaking Medicine Technology:Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability 2Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 1Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 2Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 3Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 4Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 1Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 2Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 3Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 4Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic 56522 1Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic 56522 2
... LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma ... the development,and commercialization of drug products utilizing ... today,promising results of its phase I clinical ... its ViaDerm-hPTH (1-34),product for the treatment of ...
... GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase ... XXI International,Society on Thrombosis and Haemostasis (ISTH) ... in the,prevention of venous thromboembolism (VTE) in ... comparison with,enoxaparin, the current standard of care. ...
Other Medicine Technology:TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 2TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
(Date:12/15/2009)... understand how to make an AIDS vaccine have found ... that the immune system can indeed produce cells with ... at the same time, the immune system works equally ... they have a chance to mature. , "These studies ... viral disease is under the control of immunological tolerance," ...
(Date:12/15/2009)... about-face, the secretive Central Intelligence Agency has requested documents from ... them from the CIA itself under the Freedom of Information ... ... 15, 2009 -- In a bizarre about-face, the secretive Central ... though the writer had earlier obtained them from the CIA ...
(Date:12/15/2009)... Landing on granite sand is deemed safer than wood fiber ... a child will break an arm in a fall are ... those with wood fiber surfaces, new research has found. , ... at 19 schools that had playground surfaces of either granite ... Dec. 14 in PLoS Medicine . , The risk ...
(Date:12/15/2009)... Seattle’s premier organic meal delivery service ( www.delicious-planet.com ) is ... Detox Program, Randi Carter, company founder and CEO reported today. ... ... – Seattle, WA) – Delicious Planet, Seattle’s premier organic meal ... the launch of its Delicious Planet Detox Program, Randi Carter, ...
(Date:12/15/2009)... -- At a time when Americans spend over $50 ... Dr. Raymond Hall is theorizing a painful connection between ... solution called Pillo1 ( www.pillo1.com ) to address the ... St. John,s Medical Plaza Sleep Disorders Center showed that ... sleeping position and promotes increased time spent in REM ...
Breaking Medicine News(10 mins):Health News:Biological catch-22 prevents induction of antibodies that block HIV 2Health News:CIA Requests its Own Documents from Author 2Health News:CIA Requests its Own Documents from Author 3Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 2Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 3Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 4Health News:Sleep Study Shows Pillo1 Re-Educates Body to Naturally Move Into Optimal Sleep Position and Increases REM Sleep by 21.3% 2
... learn by looking at the spines of hundreds of Finnish ... the Twin Spine Study, you find compelling proof that back ... physical strain. , The findings of the Twin Spine Study, ... a dramatic paradigm shift in the way disc degeneration is ...
... people living with chronic diseases, such as multiple sclerosis ... they must manage symptoms and treatments that cause increased ... researchers from two universities have found that people with ... depression and improve the overall quality of their lives. ...
... adolescence, study found , , TUESDAY, April 8 (HealthDay News) -- ... finds, but the impact of these factors change with age. ... from 1985 to 1986. The twins were assessed for levels ... to 14, ages 16 to 17 and ages 19 to ...
... whether it makes difference in high-risk groups, study finds ... study that weighed whether aggressively lowering cholesterol levels and ... disease is worth the effort did not produce a ... involved 499 American Indians with diabetes, found the strategy ...
... numbers tell the,story, Vicki Hoak, executive director of the ... Youth Committee today.,The Medicaid reimbursement for a year of ... an acute care hospital, the bill could be several ... Since the Governor and legislators agree that homecare is ...
... WASHINGTON, April 8, 2008 The following is a,statement of ... and is central to the health and,vitality of any democratic ... leaders have engaged in,an open and full debate over the ... SEIU,s strategies and ideas have been the subject of,an even ...
Other Medicine News:Health News:Award-winning study says back pain may be in your genes 2Health News:Increasing positive experiences decreases depression symptoms in patients with multiple sclerosis 2Health News:Genes' Influence on Fears Changes Over Time 2Health News:Aggressive Cholesterol, Blood Pressure Treatment Shows Some Benefit 2Health News:Aggressive Cholesterol, Blood Pressure Treatment Shows Some Benefit 3Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 2Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 3
Auto Plate Washer: 96-well washing. The ELx405 Auto Washer is the most precise and reliable washer available. Many unique features lower background absorbance values and increase the signal-to-noise ...
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Elisa strip reader...
Iems Incubator/Shaker expansion module for 2 module incubator/shaker. high performance microplate incubator and orbital shaker. It's superior temperature control and efficient orbital shaking reduce ...
Medicine Products: